Fan, Rui-Fang <br/><br/>
PIM-1 kinase inhibitor SMI-4a exerts antitumor effects in chronic myeloid leukemia cells by enhancing the activity of glycogen synthase kinase 3β.  [electronic resource] 

 -  Molecular medicine reports  Oct 2017 
 - 4603-4612 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1791-3004 
<br/><br/><label>Standard No.: </label>10.3892/mmr.2017.7215  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--pharmacology<br/>Apoptosis--drug effects<br/>Benzylidene Compounds--pharmacology<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Cell Survival--drug effects<br/>Glycogen Synthase Kinase 3 beta--metabolism<br/>Humans<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy<br/>Protein Kinase Inhibitors--pharmacology<br/>Protein Transport<br/>Proto-Oncogene Proteins c-pim-1--antagonists & inhibitors<br/>Thiazolidinediones--pharmacology<br/>beta Catenin--metabolism